Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.
-
Highlight
Herantis Pharma’s 1H 2023 report webinar
-
Highlight
Herantis’ R&D update webinar Thursday, January 19th, 2023
-
Highlight
Annual report 2022
Latest news and releases
-
Herantis Pharma will participate in four conferences in October 2023
Read more » -
Inside information: Herantis Pharma received a waive-off for approximately EUR 4.5 million of the principal amount of the CDNF development loans granted by Business Finland
Read more » -
Herantis Pharma will participate at Sachs 23rd Annual Biotech Forum and ØU Life Science Investor Conference in September 2023
Read more » -
Herantis Pharma: Herantis publishes 1H 2023 report today
Read more » -
Herantis Pharma Plc: First healthy volunteers dosed in the part 2 of the HER-096 Phase 1a clinical study
Read more » -
Herantis Pharma: Invitation to 1H 2023 report webinar on August 24, 2023
Read more »